NCT00704821View on ClinicalTrials.gov

PTC299 for Treatment of Advanced Cancer

PHASE1TerminatedINTERVENTIONAL

Enrollment

76

Participants

Timeline

Start Date

July 3, 2008

Primary Completion Date

February 24, 2012

Study Completion Date

February 24, 2012

Conditions

Advanced Cancer

Interventions

DRUG

PTC299

Oral

DRUG

Docetaxel

Intravenous infusion

Trial Locations (1)

10065

Memorial Sloan-Kettering Cancer Center, New York

Sponsors

Lead Sponsor

PTC Therapeutics

All Listed Sponsors

lead

PTC Therapeutics

INDUSTRY

NCT00704821 - PTC299 for Treatment of Advanced Cancer | Biotech Hunter | Biotech Hunter